期刊
SCIENCE TRANSLATIONAL MEDICINE
卷 6, 期 240, 页码 -出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3008362
关键词
-
资金
- Ovarian Cancer Research Fund, Foundation for Women's Cancer
- Cancer Prevention and Research Institute of Texas [RP101502, RP101489, RP120214, RP110595]
- National Institutes of Health [U54CA151668, CA109298, P50 CA083639, P50 CA098258, RC2GM09259, CA177909, UH2 TR000943, CA16672, U54 CA096300]
- Betty Anne Asche Murray Distinguished Professorship
RNA interference (RNAi) therapy is a rapidly emerging platform for personalized cancer treatment. Recent advances in small interfering RNA delivery and target selection provide unprecedented opportunities for clinical translation. Here, we discuss these advances and present strategies for making RNAi-based therapy a viable part of cancer management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
